{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients scheduled for elective resection of colorectal cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to either an n \u20103 FA\u2010enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of perioperative supplementation with omega\u20103 fatty acids ( n \u20103 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Outcome measures, including postoperative complications, 3\u2010year cumulative incidence of local or metastatic colorectal cancer recurrence and 5\u2010year overall survival, were compared between the groups."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 148 patients enrolled in the study"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "125 (65 patients receiving n \u20103 FA\u2010enriched ONS and 60 receiving standard ONS) were analysed"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The risk of disease recurrence at 3\u2009years was similar (relative risk 1\u00b766, 95 per cent c.i. 0\u00b765 to 4\u00b726).The 5\u2010year survival rate of patients treated with n \u20103 FA was 69\u00b72 (95 per cent c.i. 56\u00b75 to 78\u00b79) per cent, compared with 81\u00b77 (69\u00b73 to 89\u00b74) per cent in the control group ( P =\u00a00\u00b7193). After adjustment for age, stage of disease and adjuvant chemotherapy, n \u20103 FA was associated with higher mortality compared with controls (hazard ratio 1\u00b773, 95 per cent c.i. 1\u00b706 to 2\u00b783; P =\u00a00\u00b7029)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}